EP Patent

EP4563149A1 — Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers

Assigned to Pharmamar SA · Expires 2025-06-04 · 1y expired

What this patent protects

The present invention relates to the therapeutic treatment of skin cancer, particularly melanoma by using lurbinectedin, PM14 (ecubectedin) and Compound IA.

USPTO Abstract

The present invention relates to the therapeutic treatment of skin cancer, particularly melanoma by using lurbinectedin, PM14 (ecubectedin) and Compound IA.

Drugs covered by this patent

Patent Metadata

Patent number
EP4563149A1
Jurisdiction
EP
Classification
—
Expires
2025-06-04
Drug substance claim
No
Drug product claim
No
Assignee
Pharmamar SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.